Compare DexCom, Inc. (DXCM) vs Enovix Corporation (ENVX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Enovix Corporation — how do they compare? DexCom, Inc. trades at $84.11 (market cap $31.86B), while Enovix Corporation trades at $2.46 (market cap $549.72M). The key difference: DexCom, Inc. is far larger — about 58× Enovix Corporation's market cap, and DexCom, Inc. is trading nearer its 52-week high, Enovix Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Enovix Corporation for 11 Days on average.
| DXCM | ENVX | |
|---|---|---|
Market Cap | $31.86B | $549.72M |
Volume | 3,607,070 | 6,635,687 |
Sector | Health | Industrials |
52-Week High | $92.34 | $13.19 |
52-Week Low | $54.84 | $2.50 |
Typical Hold Time | 62 Days | 11 Days |
Enterprise Value | $31.32B | $611.42M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.41, showing modest daily gains of 0.13%. The stock demonstrates strong fundamental performance with consistent earnings beats and robust revenue growth, reaching $4.66 billion in 2025. Technical indicators show a bearish short-term trend with key support at $82. The company maintains impressive profitability with 20.12% net margins and 38.49% ROE, supported by growing adoption of CGM technology in diabetes care.
DXCM presents a compelling growth story with expanding market opportunities in Type 2 diabetes care. Analyst consensus remains strongly bullish with 81% buy ratings and $95.07 price target, suggesting 13% upside. Key risks include reimbursement challenges and competitive pressures. The company's strong cash flow generation and institutional support provide solid foundation for continued growth.
ENVX trades at $2.50, down 1.96% on the day, reflecting a bearish technical trend. The company is in a high-growth investment phase, with revenue increasing to $31.82 million in 2025 but accompanied by significant losses, including a net income margin of -473.89%. Recent news highlights a CEO transition and strategic focus on expanding drone battery capacity, while analyst consensus remains predominantly bullish with a $10.75 price target.
The outlook is a high-risk, high-reward proposition. The potential for substantial upside exists if the company executes its manufacturing expansion and achieves profitability, but investors face significant risk from persistent cash burn, operational challenges, and intense competition in the battery technology sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Enovix Corporation
Enovix designs and manufactures advanced silicon-anode lithium-ion batteries. Its technology aims to provide high energy density and improved performance for mobile devices and consumer electronics.
Read more on ENVX →
